Supporting Information

for

Preparation of Anthranils via Chemoselective Oxidative Radical

Cyclization of 3-(2-Azidoaryl) Substituted Propargyl Alcohols

Chao Gao¹, Jian Xu¹, Shuxian Zhu¹ Kaixia Jian¹, Qingqing Xuan^{1*}, Qiuling Song^{1,2,3*}

¹ Institute of Next Generation Matter Transformation, College of Chemical Engineering and College of Material Sciences Engineering at Huaqiao University, 668 Jimei Boulevard, Xiamen, Fujian, China, 361021.

² Key Laboratory of Molecule Synthesis and Function Discovery Fujian Province University College of Chemistry at Fuzhou University Fuzhou, Fujian, 350108 (P. R. China)

³State Key Laboratory of Organometallic Chemistry and Key Laboratory of Orga nofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academ y of Sciences, Shanghai 200032, China.

Email: <u>xuanqingqing@hqu.edu.cn</u>; <u>qsong@hqu.edu.cn</u>.

Table of Contents

I. General method	2
II. General procedure for reaction optimization	2
III. The procedure for the synthesis of 1a	3
IV. The procedure for the synthesis of 3a, 4a, 5a	4
V. Crystal data of 20	6
VI. Analytic data of products	7
VII. ¹ H and ¹³ C NMR spectra of products	15

I. General method

All chemicals were purchased from Adamas Reagent, Ltd, Energy chemical company, J&K Scientific Ltd, Alfa Aesa chemical company and so forth. Unless otherwise stated, all experiments were conducted in a Shrek bottle under N². Reactions were monitored by TLC or GC-MS analysis. Flash column chromatography was performed over silica gel (200-300 mesh).

¹H-NMR and ¹³C-NMR spectra were recorded in CDCl₃ on a Bruker Avance 500 spectrometer (500 MHz 1H, 125 MHz ¹³C) at room temperature. Chemical shifts were reported in ppm on the scale relative to CDCl₃ (δ = 7.26 for ¹H-NMR , δ = 77.00 for ¹³C-NMR) or DMSO-d6 (δ = 2.50 for 1H-NMR, δ = 39.60 for ¹³C-NMR) as an internal reference. High resolution mass spectra were recorded using Q-TOF time-of-flight mass spectrometer. Coupling constants (J) were reported in Hertz (Hz).

II. General procedure for the synthesis of 2



General optimization procedure: To a Schenk tube equipped with a stir bar, 162.5 mg of **1a** (0.5 mmol),119 mg NaS₂O₈ (0.5 mmol) were added. The Schenk tube was capped with a septum, degassed and backfilled with N₂ for at least three times. Then, the solvent (2.0 mL) and 30 uL HOAc (0.5 mmol) were added via syringe. The mixture was stirred at 100 °C for about 12 h. Then, the combined organic layer was evaporated under reduced pressure, and the product was purified by flash chromatography using petroleum ether and ethyl acetate as eluent.

III. The procedure for the synthesis of 1a

For the synthesis of 1,1-diphenylprop-2-yn-1-ol B



To a stirred solution of benzophenone **A** (5 mmol) in anhydrous THF (20 mL) under N₂ was added ethynylmagnesium bromide (0.5 mol/L in THF, 1.2 equiv) dropwise slowly at 0 °C. The mixture was allowed to warm and stir for 4 h at room temperature. After completion of the reaction as determined by TLC, the reaction mixture was quenched by aqueous saturated solution of NH₄Cl (20 mL), and extracted with ethyl acetate (2×30 mL). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, petroleum ether/ethyl acetate = 50/1) to give 1, 1-diphenylprop-2-yn-1-ol **B** as a white solid.

For the synthesis of 1-azido-2-iodobenzene D



In a round bottomed flask 2.19 g (10 mmol, 1.00 equiv.) **C** was suspended in 15 mL dry acetonitrile under air and cooled to 0 °C with an ice bath. To the stirred suspension, 2.4 mL (4.12 g, 40 mmol, 4.00 equiv.) tert-butylnitrite and 3.95 mL (3.46 g, 30 mmol, 3.00 equiv.) azidotrimethylsilane were slowly added. The reaction mixture was stirred for 2 h and allowed to warm to room temperature. Then, the volatiles were evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using cyclohexane/ethyl acetate (20:1, v/v) as eluent. After purification, 0.720 g (4.50 mmol, 49%) 1-azido-2-iodobenzene **D**.

For the synthesis of 3-(2-azidophenyl)-1,1-diphenylprop-2-yn-1-ol 1a



To a solution of 1-azido-2-iodobenzene **D** (1.23 g, 5 mmol) in triethylamine (20 mL) was added PdCl₂(PPh₃)₂ (70.2 mg, 0.100 mmol) and CuI (9.5 mg,0.050 mmol) at room temperature, and the mixture was stirred for 15 min at r.t. under N₂ before addition of 1,1-diphenylprop-2-yn-1-ol **B** (1.25 g, 6.0 mmol). The resulting mixture was stirred for 4 h at 80 $_{0}$ C under N₂. Then, the mixture was allowed to cool to room temperature, and added saturated NH₄Cl solution, and extracted with ethyl acetate. The combine organic layer was washed with saturated NaCl solution ,dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silicagel, petroleum ether/ethyl acetate= 20:1) to give 1,1-diphenyl-3-(2-(phenylethynyl)phenyl)prop-2-yn-1-ol **1a** (1.38 g,yield: 75 %) as yellow solid.

IV. The procedure for the synthesis of 3a, 4a, 5a

For the synthesis of 1-(2-aminophenyl)-3,3-diphenylprop-2-en-1-one 3a



To a Schenk tube equipped with a stir bar, **2a** (0.2 mmol), CuI (0.02 mmol) were added. The Schenk tube was capped with a septum, degassed and backfilled with N₂ for at least three times. Then, the solvent (2.0 ml) and CF₃COOH (0.4 mmol) were added via syringe. The mixture was stirred at 110 °C for about 12 h. Then, the combined organic layer was evaporated under reduced pressure, and the product was purified by flash chromatography using petroleum ether and ethyl acetate as eluent. Purification by column chromatography (silica gel, eluent: petroleum ether/ethyl acetate = 50:1) afforded product 3a as a yellow solid in 47% yield.

For the synthesis of N-(2-(3,3-diphenylacryloyl)phenyl)-2-oxo-2-phenylacetamide 4a



In a round bottomed flask **2a** (0.2 mmol), α -keto acid (0.4 mmol), CuBr₂ (0.01 equiv) and PPh₃ (0.04 equiv,). After the addition of DCE (3 mL), the reaction was stirred at 110 °C for 12 h. The reaction mixture was filtered through celite and concentrated in vacuo. Purification by column chromatography (silica gel, eluent: petroleum ether/ethyl acetate = 50:1) afforded product **4a** as a yellow solid in 56% yield. For the synthesis of N-(2-(3,3-diphenylacryloyl)phenyl)benzamide **5a**



In a 25 mL sealed tube, a mixture of **2a** (0.2 mmol, 1 equiv.), aryl iodides 2 (0.5 mmol, 2.5 equiv.), Pd/C (2.1 mg, 10 mol %), Mo(CO)₆ (0.1 mmol, 0.5 equiv.), Et₃N (0.6 mmol, 3 equiv.), and TBAB (0.006 mmol, 3 mol %) in distilled water (2 mL) was stirred at 80 °C under air. After 18 h, the mixture was cooled to room temperature. The residue was diluted with H₂O solution (10 mL) and extracted with EtOAc (3×10 mL). The solvent was then evaporated under vacuum. The crude products were purified by using column chromatography on silica gel (pentane/ethyl acetate) to give product **5a** as a yellow solid in 57% yield.

V. Crystal data of 20

Crystallographic data for compound **20** (CCDC- 1915267) has been deposited with the Cambridge Crystallographic Data Centre, Copies of the data can be obtained, free of charge, on application to CCDC (Email:deposit@ccdc.cam.ac.uk).



Bond precisio	on: C-C	= 0.0042 A	Wavelength=0.71073	
Cell:	a=14.1901(8)	b=13.1981(9)	c=9.2973(6)	
	alpha=90	beta=103.858(14) gamma=90	
Temperature:	293 K			
Calculated		d	Reported	
Volume	1690.54(1	.9)	1690.54(19)	
Space group	P 21/c		P 1 21/c 1	
Hall group	ll group -P 2ybc		-P 2ybc	
Moiety formu	ıla C21 H13	Cl F N O	C21 H13 Cl F N O	
Sum formula	C21 H13	Cl F N O	C21 H13 CI F N O	
Mr	394.77		394.77	
Dx,g cm-3	1.374		1.374	
Ζ	4		4	
Mu (mm-1)	0.244		0.244	
F000	720.0		720.0	
F000'	720.91		720.91	
h,k,lmax	19,18,12		19,17,12	
Nref	4651		3894	
Tmin,Tmax			0.244,1.000	
Tmin'				
Correction method= Not given			() = 20.247	
Data completeness= 0.837		Ineta	1 neta(max) = 29.347	
R(reflections)= 0.0549(2057)		wR2	(reflections)= 0.1912(3894)	
S = 0.920	Np	ar= 226		

VI. Analytic data of products

3-(2,2-diphenylvinyl)benzo[c]isoxazole (2a)



Compound **2a**:Yellow solid (87% yield, 129 mg) ¹H NMR (500 MHz, CDCl₃) δ 7.45 (d, *J* = 9.0 Hz, 1H), 7.42 – 7.34 (m, 8H), 7.29 (dd, *J* = 7.5, 2.1 Hz, 2H), 7.20 – 7.14 (m, 2H), 6.72 (dd, *J* = 3.2, 1.1 Hz, 2H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 164.0, 157.1, 148.4, 141.8, 139.4, 130.4, 130.3, 129.0, 128.7, 128.7, 128.5, 128.3, 123.6, 120.4, 116.0, 115.0, 112.2.

3-(2,2-diphenylvinyl)-5-methylbenzo[c]isoxazole (2b)



Compound **2b**:Yellow solid (33% yield, 51.3 mg) ¹H NMR (500 MHz, CDCl₃) δ 7.43 – 7.36 (m, 9H), 7.33 – 7.28 (m, 2H), 7.20 (s, 1H), 7.06 – **S6**

6.99 (m, 1H), 6.29 (d, J = 1.0 Hz, 1H), 2.13 (d, J = 0.5 Hz, 3H). ¹³C NMR (12 MHz, CDCl₃) δ 163.7, 163.3, 157.1 (d, J = 15.7 Hz), 146.0, 142.0, 141.3, 140.9, 140.5, 138.5, 130.5 (t, J = 12.3 Hz), 129.9, 129.4, 128.94 (d, J = 10.1 Hz), 128.7, 128.4 (d, J = 4.1 Hz), 128.1 (d, J = 8.5 Hz), 127.4 (d, J = 19.1 Hz), 123.9 , 123.6, 120.3 (d, J = 9.2 Hz), 116.3 (d, J = 6.0 Hz), 115.2 (s), 115.0 (s), 113.4 (s), 110.0 HRMS (ESI, m/z) calcd for C₂₂H₁₇NO [M+H]+: 312.1383; found: 312.1385.

3-(2,2-diphenylvinyl)-5-fluorobenzo[c]isoxazole (2c)



Compound **2c**:Yellow solid (74% yield, 116.6 mg)¹H NMR (500 MHz, Chloroform-*d*) δ 7.49 (dd, J = 9.5, 4.6 Hz, 1H), 7.44 – 7.35 (m, 8H), 7.30 (dt, J = 6.6, 1.6 Hz, 2H), 7.17 (s, 1H), 7.01 (ddd, J = 9.6, 8.4, 2.3 Hz, 1H), 6.00 (dd, J = 9.3, 2.3 Hz, 1H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 155.4, 148.1, 141.6, 139.3, 130.3, 129.1, 128.9, 128.9, 128.5, 128.3, 123.5, 123.3, 117.6, 117.5, 112.4, 112.4, 102.6, 102.4. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -115.3. HRMS (ESI, m/z) calcd for

C₂₁H₁₄FNO [M+H]+: 316.1132; found: 316.1128

3-(2,2-diphenylvinyl)benzo[c]isoxazole (2d)



Compound **2d:**Yellow solid (80% yield, 132.5 mg)¹H NMR (500 MHz, CDCl₃) δ 7.56 – 7.27 (m, 8H), 7.27 – 7.18 (m, 3H), 7.15 (s, 1H), 7.00 (d, J = 8.7 Hz, 1H), 6.92 – 6.82 (m, 1H).¹³C NMR (125 MHz, CDCl₃) δ 164.0, 155.7, 148.9, 141.39 (s), 139.2, 132.1, 130.3, 129.2, 128.9 (d, J = 14.1 Hz), 128.5, 128.3 (s), 119.3, 116.6, 115.7, 112.2. HRMS (ESI, m/z) calcd for C₂₁H₁₄CINO [M+H]+: 332.0837; found: 316.0835

5-bromo-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2e)



Compound **2e:**Yellow solid (77% yield, 128.0 mg)¹H NMR (500 MHz, CDCl₃) δ 7.48 (t, J = 7.4 Hz, 1H), 7.44 – 7.34 (m, 8H), 7.30 (d, J = 7.4 Hz, 2H), 7.24 – 7.16 (m, 2H), 6.51 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 163.9, 155.7, 149.0, 141.4, 139.2, 134.2, 130.3, 129.3, 128.96 (d, J = 16.3 Hz), 128.6, 128.3, 123.0,117.0,116.7, 116.3, 112.3 HRMS (ESI, m/z) calcd for C₂₁H₁₄BrNO [M+H]+: 376.0332; found: 376.0332

3-(2,2-diphenylvinyl)-4-fluorobenzo[c]isoxazole (2f)



Compound **2f:** Yellow solid (63% yield, 99.2 mg) ¹H NMR (500 MHz, CDCl₃) δ 7.44 – 7.36 (m, 8H), 7.33 – 7.28 (m, 2H), 7.17 (s, 1H), 7.06 – 6.98 (m, 1H), 6.66 – 6.61 (m, 1H), 6.56 – 6.49 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 164.7, 164.5, 162.5, 157.4 (d, *J* = 13.0 Hz), 149.4, 141.5, 139.2, 130.3, 129.3, 128.9 (d, *J* = 18.4 Hz), 128.5, 128.4, 123.1 (d, *J* = 11.1 Hz), 116.5, 116.3, 113.5, 112.0, 97.4, 97.2. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -106.9. HRMS (ESI, m/z) calcd for C₂₁H₁₄FNO

[M+H]+: 316.1132; found: 316.1136

4-chloro-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2g)



Compound **2g:**Yellow solid (78% yield, 129.1 mg) ¹H NMR (500 MHz, CDCl₃) δ 7.47 (s, 1H), 7.45 – 7.34 (m, 8H), 7.30 (d, *J* = 6.3 Hz, 2H), 7.18 (s, 1H), 6.70 – 6.60 (m, 1H), 6.55 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 164.9, 157.3, 149.5, 141.4, 139.2, 136.7, 130.3, 129.3, 128.9 (d, *J* = 18.2 Hz), 128.6, 128.4, 125.3, 122.0, 114.1, 113.6, 112.0. HRMS (ESI, m/z) calcd for C₂₁H₁₄ClNO [M+H]+: 332.0837; found: 332.0834

4-bromo-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2h)



Compound **2h**:Yellow solid (73% yield, 148.2 mg)¹H NMR (500 MHz, CDCl₃) δ 7.70 – 7.67 (m, 1H), 7.42 – 7.36 (m, 8H), 7.32 – 7.27 (m, 2H), 7.18 (s, 1H), 6.79 – 6.72 (m, 1H), 6.46 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.1, 157.7, 149.5, 141.4, 139.2, 130.3, 129.3, 128.9 (d, *J* = 19.2 Hz), 128.5 (d, *J* = 19.9 Hz), 127.5, 125.3, 121.0, 117.1, 114.2, 112.0. HRMS (ESI, m/z) calcd for C₂₁H₁₄BrNO [M+H]+: 376.0332; found: 376.0332

3-(2,2-diphenylvinyl)-5-nitrobenzo[c]isoxazole (2i)



Compound **2i**:Yellow solid (76% yield, 130.0 mg)¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, J = 9.1 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.40 – 7.19 (m, 8H), 6.99 (d, J = 8.8 Hz, 1H), 6.94 (s, 1H), 6.91 – 6.83 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 170.0, 156.8, 152.5, 142.1 (d, J = 348.9 Hz), 149.8 – 130.2, 129.2, 128.6 (d, J = 15.8 Hz), 124.4 (s), 121.3 , 116.3, 113.7, 111.7. HRMS (ESI, m/z) calcd for C₂₁H₁₄BrN₂O₃ [M+H]+: 343.1077; found: 376.1075

3-(2,2-diphenylvinyl)benzo[c]isoxazole-5-carbonitrile (2j)



Compound **2j**:Yellow solid (73% yield, 117.5 mg)¹H NMR (500 MHz, CDCl₃) δ 7.55 – 7.50 (m, 2H), 7.48 – 7.37 (m, 8H), 7.33 – 7.29 (m, 2H), 7.22 – 7.19 (m, 1H), 6.68 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 167.4, 156.0, 151.5, 140.8, 138.9, 130.2 (d, *J* = 13.6 Hz), 129.9, 129.6, 129.3, 128.7, 128.5, 118.3, 116.7, 114., 111.9, 107.0. HRMS (ESI, m/z) calcd for C₂₂H₁₄BrN₂O [M+H]+: 323.1179; found: 323.1182

methyl 3-(2,2-diphenylvinyl)benzo[c]isoxazole-5-carboxylate (2k)



Compound **2k**: Yellow solid (84% yield, 149.2 mg)¹H NMR (500 MHz, CDCl₃) δ 7.81 – 7.73 (m, 1H), 7.54 (s, 1H), 7.50 – 7.46 (m, 1H), 7.46 – 7.37 (m, 8H), 7.34 – 7.28 (m, 2H), 3.87 (s, 3H). ¹³C NMR (12 MHz, CDCl₃) δ 167., 166., 157.32 , 150.6, 141.3, 139.0, 130.2, 129.8, 129.5, 129.2, 128.8, 128.5 (d, *J* = 16.3 Hz), 125.9, 125.4, 115.4, 115.0, 111.6, 52.1. HRMS (ESI, m/z) calcd for C₂₃H₁₇NO₃ [M+H]+: 356.1281; found: 356.1284

3-(2,2-diphenylvinyl)-5-(trifluoromethyl)benzo[c]isoxazole (2l)



Compound **21:**Yellow solid (64% yield, 116.8 mg)¹H NMR (500 MHz, CDCl₃) δ 7.57 (d, J = 9.4 Hz, 1H), 7.47 – 7.37 (m, 8H), 7.33 – 7.25 (m, 4H), 6.77 (d, J = 0.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 167.1, 157.0, 150.5, 141.2, 139.0, 130.2, 129.51 (d, J = 14.1 Hz), 129.0, 128.6, 128.4, 126.9, 126.12 (d, J = 2.7 Hz), 125.7, 125.5, 125.2, 124.0, 124.7, 122.5, 120.53 (q, J = 5.3 Hz), 116.5, 113.8, 112.2, ¹⁹F NMR (471 MHz, Chloroform-d) δ -63.4. HRMS (ESI,

m/z) calcd for $C_{22}H_{14}F_3NO [M+H]+: 366.1100$; found: 366.1102

5-chloro-3-(2,2-diphenylvinyl)-7-fluorobenzo[c]isoxazole (2m)



Compound **2m**:Yellow solid (91% yield, 172.4 mg)¹H NMR (500 MHz, CDCl₃) δ 7.53 – 7.48 (m, 1H), 7.48 – 7.38 (m, 7H), 7.35 – 7.29 (m, 2H), 7.20 (s, 1H), 6.90 – 6.78 (m, 1H), 6.22 (d, *J* = 1.4 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.2 (d, *J* = 3.4 Hz), 151.1, 150.0, 149.1 (d, *J* = 16.6 Hz), 141.1, 139.0, 130.2, 129.5, 129.2, 128.9, 128.6, 128.4, 127.8 (d, *J* = 6.4 Hz), 117.5 (d, *J* = 4.5 Hz), 115.6 (d, *J* = 5.8 Hz), 114.9 (d, *J* = 19.0 Hz), 111.67 (s). ¹⁹F NMR (471 MHz, Chloroform-*d*) δ –

123.7. HRMS (ESI, m/z) calcd for C₂₁H₁₃CIFNO [M+H]+: 350.0742; found: 350.0745

4-chloro-3-(2,2-diphenylvinyl)-5-fluorobenzo[c]isoxazole (2n)



Compound **2n**:Yellow solid (98% yield, 187.2 mg)¹H NMR (500 MHz, CDCl₃) δ 7.48 – 7.44 (m, 2H), 7.43 – 7.36 (m, 6H), 7.33 (d, *J* = 3.6 Hz, 2H), 7.29 – 7.22 (m, 2H), 6.62 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 183.1 (d, *J* = 3.5 Hz), 157.4, 155.5, 144.9, 139.5, 137.3, 133.4, 132.7, 130.5, 130.2, 129.0 (d, *J* = 2.7 Hz), 128.8, 128.2, 123.9 (d, *J* = 7.6 Hz), 122.7, 122.5, 116.9 (d, *J* = 10.0 Hz), 109.2, 109.0. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -122.3. HRMS (ESI, m/z) calcd for C₂₁H₁₃CIFNO

[M+H]+: 350.0742; found: 350.0743

3-(2,2-diphenylvinyl)-5-ethyl-7-iodobenzo[c]isoxazole (20)



Compound **20**:Yellow solid (72% yield, 167.4 mg)¹H NMR (500 MHz, CDCl₃) δ 7.64 (s, 1H), 7.48 – 7.31 (m, 11H), 6.53 (s, 1H), 2.59 (d, *J* = 7.6 Hz, 2H), 1.20 (t, *J* = 7.6 Hz, 3H).¹³C NMR (125 MHz, CDCl₃) δ 184.7, 151.0, 143.5, 139.7, 137.8, 137.6, 132.9, 131.6, 130.6, 130.2, 129.0, 128.8, 128.6, 128.1, 123.8, 123.5, 27.9, 15.8 HRMS (ESI, m/z) calcd for C₂₃H₁₈INO [M+H]+: 452.0506; found: 452.0503



3-(2,2-diphenylvinyl)-7-iodo-5-isopropylbenzo[c]isoxazole (2p)
Compound 2p:Yellow solid (98% yield, 227.9 mg)¹H NMR (500 S9

MHz, CDCl₃) δ 7.67 (d, J = 1.5 Hz, 1H), 7.49 – 7.32 (m, 11H), 6.54 (s, 1H), 2.89 – 2.81 (m, 1H), 1.23 (d, J = 6.9 Hz, 6H).¹³C NMR (125 MHz, CDCl₃) δ 184.8 151.1, 142.7, 142.4, 139.8 (s), 137.6, 133.0, 131.7, 130.6, 130.2, 129.0, 128.8, 128.6, 128.1, 123.8, 122.1, 33.4, 24.1. HRMS (ESI, m/z) calcd for C₂₄H₂₀INO [M+H]+: 466.0662; found: 466.0661

5-(tert-butyl)-3-(2,2-diphenylvinyl)-7-iodobenzo[c]isoxazole (2q)



Compound **2q:**Yellow solid (73% yield, 184.4 mg)¹H NMR (500 MHz, CDCl₃) δ 7.64 (s, 1H), 7.48 – 7.31 (m, 11H), 6.53 (s, 1H), 2.59 (d, *J* = 7.6 Hz, 2H), 1.57 (s, 2H), 1.20 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 184.9, 150.8, 145.1, 141.4, 139.7, 137.6 133.0, 131.7, 130.6, 130.2, 129.0, 128.8, 128.6, 128.1, 123.5, 121.2, 34.5, 31.4. HRMS (ESI, m/z) calcd for C₂₅H₂₂INO [M+H]+: 466.0662; found: 466.0661

3-(2,2-di-p-tolylvinyl)benzo[c]isoxazole (2r)



Compound **2r**:Yellow solid(33% yield, 64.9 mg)¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.21 – 7.15 (m, 7H), 7.13 (s, 1H), 6.81 – 6.71 (m, 2H), 2.40 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 164.4, 157.1, 148.6, 139.2 (d, J = 1.4 Hz), 138.6, 136.5, 130.3 (d, J = 18.2 Hz), 129.2 (d, J = 17.6 Hz), 128.32, 123.2, 120.6, 115.9, 115.0, 111.1, 21.4 (d, J = 14.3 Hz). HRMS (ESI, m/z) calcd for C₂₃H₁₉NO [M+H]+: 326.1539; found: 326.1543

3-(2,2-bis(3,5-dimethylphenyl)vinyl)benzo[c]isoxazole (2s)



Compound **2s:** Yellow solid (43% yield, 82.3 mg)¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, J = 9.0 Hz, 1H), 7.22 – 7.16 (m, 1H), 7.13 (s, 1H), 7.05 – 7.00 (m, 4H), 6.90 (s, 2H), 6.75 – 6.65 (m, 2H), 2.33 (s, 6H), 2.27 (s, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 164., 157.1, 149.0, 142.1, 139.32, 138.0 (d, J = 15.4 Hz), 130.7, 130.3 (d, J = 10.9 Hz), 127.9 , 126.2 , 122.2, 120.8, 115.8, 114.9, 112.0 , 21.3 (d, J = 2.7 Hz). HRMS (ESI, m/z) calcd for C₂₅H₂₃NO [M+H]+: 354.1852; found: 354.1855

3-(2,2-bis(4-fluorophenyl)vinyl)benzo[c]isoxazole (2t)



Compound **2t**: Yellow solid (53% yield, 109.1 mg)¹H NMR (500 MHz, CDCl₃) δ 7.48 (d, J = 8.7 Hz, 1H), 7.36 (s, 2H), 7.32 – 7.17 (m, 3H), 7.09 (d, J = 18.1 Hz, 5H), 6.93 (d, J = 8.5 Hz, 1H), 6.88 – 6.77 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 164.3, 164.0, 163.4, 162.4, 162.0, 157.0, 146.12, 137.8 (d, J = 3.2 Hz), 135.1 (d, J = 3.5 Hz), 132.1 (d, J = 510

= 8.2 Hz), 130.61, 130.1 (d, J = 8.3 Hz), 123.9, 120.0, 116.3, 115.9, 115.7 (d, J = 9.0 Hz), 115.5 (s), 115.2 (s), 111.9. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -111.8, -112.1. HRMS (ESI, m/z) calcd for C₂₁H₁₃F₂NO [M+H]+: 334.1038; found: 334.1039

3-(2,2-bis(4-chlorophenyl)vinyl)benzo[c]isoxazole (2u)



Compound **2u**: Yellow solid (51% yield, 93.1 mg)¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, J = 9.0 Hz, 1H), 7.40 – 7.28 (m, 6H), 7.27 – 7.18 (m, 3H), 7.15 (s, 1H), 7.00 (d, J = 8.7 Hz, 1H), 6.92 – 6.82 (m, 1H). ¹³C NMR (125MHz, CDCl₃) δ 163.0, 157.0, 145.6, 139.8, 137.4, 135.3, 134.9, 131.5, 130.7, 129.5, 129.0, 128.8, 124.2, 119.9, 116.7, 115.3, 112.2. HRMS (ESI, m/z) calcd for C₂₁H₁₃Cl₂NO [M+H]+: 366.0447; found: 366.0445

3-(2,2-bis(4-bromophenyl)vinyl)benzo[c]isoxazole (2v)



Compound **2v:** Yellow solid (43% yield, 97.4 mg)¹H NMR (500 MHz, CDCl₃) δ 7.57 – 7.36 (m, 9H), 7.31 (s, 1H), 7.19 (s, 1H), 7.09 (d, *J* = 9.3 Hz, 1H), 6.36 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 164.0, 155.7, 148.9, 141.4, 139.2, 132.1 (d, *J* = 19.1 Hz), 131.8 (d, *J* = 1.9 Hz), 130.3, 129.7, 129.3, 129.1 – 128.8, 128.5, 128.3, 119.3, 116.6, 115.7, 112.2 HRMS (ESI, m/z) calcd for C₂₁H₁₃Br₂NO [M+H]+: 453.9437; found: 453.9435

3-(2-phenyl-2-(p-tolyl)vinyl)benzo[c]isoxazole (2w)



Compound **2w:** Yellow solid (44% yield, 68.4 mg)¹H NMR (500 MHz, CDCl₃) δ 7.50 – 7.46 (m, 1H), 7.44 – 7.37 (m, 4H), 7.34 – 7.29 (m, 2H), 7.23 – 7.15 (m, 5H), 6.84 – 6.72 (m, 2H), 2.41 (d, *J* = 3.4 Hz, 3H).¹³C NMR (125 MHz, CDCl₃) δ 164.2, 157.1 (d, *J* = 2.0 Hz), 148.6, 148.4, 142.0, 139.5, 139,3 138.9, 138.7, 130.4 (dd, *J* = 18.3, 4.9 Hz), 129.3(d, *J* = 16.1 Hz), 129.0, 128.7 (d, *J* = 2.9 Hz), 128.4 (d, *J* = 2.6 Hz), 128.3, 123.4 (d, *J* = 3.7 Hz), 120.5 (d, *J* = 8.9 Hz), 115.0 (d, *J* = 2.4 Hz), 111.8, 111.4, 21.4 (d, *J* = 14.7 Hz). HRMS (ESI, m/z) calcd for C₂₂H₁₇NO [M+H]+: 312.1383; found:

312.1385

3-(2-(3,4-dimethylphenyl)-2-phenylvinyl)benzo[c]isoxazole (2x)



Compound **2x**:Yellow solid (61% yield, 99.1 mg)¹H NMR (500 MHz, CDCl₃) δ 7.50 – 7.35 (m, 5H), 7.34 – 7.28 (m, 1H), 7.22 – 7.10 (m, 4H), 7.08 – 7.02 (m, 1H), 6.80 – 6.70 (m, 2H), 2.34 – 2.19 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 164.3 (d, *J* = 1.9 Hz), 157.1 (d, *J* = 3.4 Hz), 148.7, 148.6, 142.2, 139.6, 139.4, 138.0, 137.2, 136.8 (d, *J* = 10.8 Hz), 131.3, 130.5 – 130.2 (m), 129.8 (d, *J* = 11.8 Hz), 129.4 , 128.9, 128.6, 128.4, 127.8, 126.0, 123.3 (d, *J* = 10.9 Hz), 120.6 (d, *J* = 17.1 Hz), 116.01 115.8,

115.0, 111.7, 111.4, 19.8 (dd, J = 17.3, 12.0 Hz). HRMS (ESI, m/z) calcd for C₂₃H₁₉NO [M+H]+:

326.1539; found: 326.1543

3-(2-(4-methoxyphenyl)-2-phenylvinyl)benzo[c]isoxazole (2y)



Compound **2y:**Yellow solid (20% yield, 43.6 mg)¹H NMR (500 MHz, CDCl₃) δ 7.48 (d, J = 9.1 Hz, 1H), 7.42 – 7.33 (m, 5H), 7.26 – 7.13 (m, 3H), 7.10 (s, 1H), 6.93 – 6.87 (m, 2H), 6.83 (d, J = 8.8 Hz, 1H), 6.79 – 6.72 (m, 1H), 3.85 (d, J = 2.7 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 164.4, 160.0, 157.1, 142.3, 131.8, 131.6, 130.4 (d, J = 18.2 Hz), 129.7, 129.0, 128.5 (t, J = 14.6 Hz), 123.4, 120.6, 115.0, 114.0 (d, J = 22.1 Hz), 111.6, 55.3. HRMS (ESI, m/z) calcd for C₂₂H₁₇NO₂ [M+H]+: 328.1332; found: 328.1333

3-(2-(2-chlorophenyl)-2-(3-chlorophenyl)vinyl)benzo[c]isoxazole (2z)



Compound **2z**:Yellow solid (46% yield, 84.2 mg)¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, J = 9.1 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.40 – 7.19 (m, 8H), 6.99 (d, J = 8.8 Hz, 1H), 6.94 (s, 1H), 6.91 – 6.83 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 162.6, 157.0, 145.0, 141.0, 137.3, 134.7, 133.3, 131.6, 131.0, 130.7, 130.4, 129.9, 128.6, 126.9, 124.3, 120.0, 116.8, 115.8, 115.3 HRMS (ESI, m/z) calcd for C₂₁H₁₃Cl₂NO [M+H]+: 366.0447; found: 366.0447

5-chloro-7-fluoro-3-(2-(4-fluorophenyl)-2-(4-methoxyphenyl)vinyl)benzo[c]isoxazole (2aa)



Compound **2aa**: Yellow solid (40% yield, 69.0 mg)¹H NMR (500 MHz, CDCl₃) δ 7.50 – 7.45 (m, 1H), 7.40 – 7.36 (m, 1H), 7.35 – 7.31 (m, 1H), 7.31 – 7.27 (m, 1H), 7.24 – 7.17 (m, 2H), 7.11 – 7.03 (m, 3H), 6.95 – 6.82 (m, 3H), 6.81 – 6.75 (m, 1H), 3.85 (d, *J* = 5.0 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 157.1 (d, *J* = 13.4 Hz), 218.3 – 115.2, 132.10 (d, *J* = 8.2 Hz), 131.8, 130.5 (d, *J* = 7.1 Hz), 130.3 (d, *J* = 8.2 Hz), 129.7, 123.5 (d, *J* = 3.6 Hz), 120.5, 120.3 (d, *J* = 41.8 Hz), 120.9 – 115.9, 118.1 (dd, *J* = 555.5, 37.8 Hz), 115.0 (d, *J* = 3.9 Hz), 114.1, 114.0, 55.4 (d, *J* = 11.6 Hz). ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -63.4. HRMS

(ESI, m/z) calcd for C₂₂H₁₆FNO₂ [M+H]+: 346.1238; found: 346.1239



3-((9H-thioxanthen-9-ylidene)methyl)benzo[c]isoxazole (2ab)

Compound **2aa:** (47% yield, 76.8 mg)¹H NMR (500 MHz, CDCl₃) δ 7.85 - 7.79 (m, 1H), 7.61 - 7.47 (m, 4H), 7.42 - 7.27 (m, 3H), 7.25 - 7.19 (m, 1H), 7.18 - 7.11 (m, 1H), 7.01 (s, 1H), 6.88 (d, *J* = 8.8 Hz, 1H), 6.82 - 6.76 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 163.9, 155.7, 149.0, 141.4, 139.2, 134.2, 130.3, 129.3, 129.0(d, *J* = 16.3 Hz), 128.6, 128.3, 123.0, 117.0, 116.7, 116.3, 112.3. HRMS (ESI, m/z) calcd for C₂₁H₁₃NOS [M+H]+: 328.0791; found: 328.0791

1-(2-aminophenyl)-3,3-diphenylprop-2-en-1-one (3a)



Compound **3a:** (47% yield, 28.2 mg)¹H NMR (500 MHz, Chloroform-*d*) δ 7.82 (dd, J = 8.1, 1.6 Hz, 1H), 7.37 (s, 5H), 7.29 (dd, J = 5.0, 1.8 Hz, 3H), 7.21 (ddd, J = 7.6, 4.2, 2.6 Hz, 3H), 7.06 (s, 1H), 6.65 – 6.55 (m, 2H), 6.15 (s, 2H). ¹³C NMR (125 MHz, Chloroform-*d*) δ 195.4, 151.7, 150.5, 141.7, 139.3, 134.3, 132.5, 129.7, 128.9, 128.5, 128.4, 128.1, 128.1, 126.4, 119.4, 117.0, 115.7. HRMS (ESI, m/z) calcd for C₂₁H₁₇NO [M+H]+: 300.1383;

found: 300.1389

N-(2-(3,3-diphenylacryloyl)phenyl)-2-oxo-2-phenylacetamide (4a)



Compound **4a**: (56% yield, 48.3 mg)¹H NMR (500 MHz, Chloroformd) δ 12.37 (s, 1H), 8.72 (dd, J = 8.4, 1.1 Hz, 1H), 8.38 – 8.30 (m, 2H), 7.98 (dd, J = 7.9, 1.6 Hz, 1H), 7.64 (td, J = 7.3, 1.4 Hz, 1H), 7.57 – 7.45 (m, 4H), 7.42 – 7.36 (m, 5H), 7.28 (s, 1H), 7.25 (d, J = 0.7 Hz, 1H), 7.19 – 7.16 (m, 2H), 7.12 (td, J = 7.6, 1.2 Hz, 1H), 7.00 (s, 1H). ¹³C NMR (126 MHz, Chloroform-d) δ 196.8, 187.2, 160.8, 154.7,

141.0, 138.9, 138.7, 134.4, 134.2, 133.3, 132.0, 131.2, 129.8, 129.5, 128.7, 128.7, 128.5, 128.2, 125.4, 125.2, 123.6, 121.0. HRMS (ESI, m/z) calcd for $C_{29}H_{21}NO_3$ [M+H]+: 432.1594; found: 432.1601

N-(2-(3,3-diphenylacryloyl)phenyl)benzamide (5a)



Compound **5a**: (57% yield, 45.9 mg)¹H NMR (500 MHz, Chloroform-*d*) δ 7.82 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.37 (s, 5H), 7.29 (dd, *J* = 5.0, 1.8 Hz, 3H), 7.21 (ddd, *J* = 7.6, 4.2, 2.6 Hz, 3H), 7.06 (s, 1H), 6.65 – 6.55 (m, 2H), 6.15 (s, 2H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 197.9, 166.1, 154.0, 141.1, 141.0, 138.7, 134.9, 134.7, 132.2, 131.9, 129.8, 129.5, 128.8, 128.7, 128.5, 128.3, 127.6, 125.8, 123.8, 122.5,

120.9. HRMS (ESI, m/z) calcd for C₂₈H₂₁NO₂ [M+H]+: 404.1645; found: 404.1640

VII. ¹H ¹³C and F¹⁹ NMR spectra of products

3-(2,2-diphenylvinyl)benzo[c]isoxazole (2a)





3-(2,2-diphenylvinyl)-5-methylbenzo[c]isoxazole (2b) S14





3-(2,2-diphenylvinyl)-5-fluorobenzo[c]isoxazole (2c)







3-(2,2-diphenylvinyl)benzo[c]isoxazole(2d)





5-bromo-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2e)





3-(2,2-diphenylvinyl)-4-fluorobenzo[c]isoxazole (2f) S19







4-chloro-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2g)





4-bromo-3-(2,2-diphenylvinyl)benzo[c]isoxazole (2h)





3-(2,2-diphenylvinyl)-5-nitrobenzo[c]isoxazole (2i)





3-(2,2-diphenylvinyl)benzo[c]isoxazole-5-carbonitrile (2j)







methyl 3-(2,2-diphenylvinyl)benzo[c]isoxazole-5-carboxylate (2k)





3-(2,2-diphenylvinyl)-5-(trifluoromethyl)benzo[c]isoxazole (2l)























3-(2,2-diphenylvinyl)-5-ethyl-7-iodobenzo[c]isoxazole (20)





3-(2,2-diphenylvinyl)-7-iodo-5-isopropylbenzo[c]isoxazole (2p)





5-(tert-butyl)-3-(2,2-diphenylvinyl)-7-iodobenzo[c]isoxazole (2q)















3-(2,2-bis(4-fluorophenyl)vinyl)benzo[c]isoxazole (2t)







3-(2,2-bis(4-chlorophenyl)vinyl)benzo[c]isoxazole (2u)





3-(2,2-bis(4-bromophenyl)vinyl)benzo[c]isoxazole(2v)





3-(2-phenyl-2-(p-tolyl)vinyl)benzo[c]isoxazole (2w)







3-(2-(3,4-dimethylphenyl)-2-phenylvinyl)benzo[c]isoxazole (2x)











3-(2-(2-chlorophenyl)-2-(3-chlorophenyl)vinyl)benzo[c]isoxazole (2z)





5-chloro-7-fluoro-3-(2-(4-fluorophenyl)-2-(4- methoxyphenyl)vinyl)benzo[c]isoxazole (2aa)







3-((9H-thioxanthen-9-ylidene)methyl)benzo[*c*]isoxazole (2ab)











N-(2-(3,3-diphenylacryloyl)phenyl)-2-oxo-2-phenylacetamide (4a)







